Immatics (IMTX) Cash from Financing Activities (2019 - 2025)
Immatics (IMTX) reported Cash from Financing Activities of $115.9 million for Q4 2025, down 25.91% on a YoY basis from $156.4 million in Q4 2024, and up 13604.66% sequentially from -$858086.4 in Q3 2025.
Immatics (IMTX) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Immatics (IMTX) has 7 years of Cash from Financing Activities data on file, last reported at $115.9 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities fell 25.91% year-over-year to $115.9 million; the trailing twelve-month figure through Dec 2025 stood at $113.4 million (down 67.09% YoY), and the FY2025 full-year result was $110.0 million, down 68.21% from the prior year.
- Cash from Financing Activities advanced to $115.9 million in Q4 2025, from -$858086.4 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $189.7 million in Q1 2024 to a low of -$1.6 million in Q2 2021.
- A 5-year average of $33.7 million and a median of -$639942.7 in 2021 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities plunged 482.48% in 2021 and jumped 20511.49% in 2024, its largest moves.
- Tracing IMTX's Cash from Financing Activities over 5 years: stood at -$670367.0 in 2021, then jumped by 16154.62% to $107.6 million in 2022, then sank by 100.97% to -$1.0 million in 2023, then soared by 15054.62% to $156.4 million in 2024, then fell by 25.91% to $115.9 million in 2025.
- Business Quant data shows IMTX's Cash from Financing Activities at $115.9 million in Q4 2025, -$858086.4 in Q3 2025, and -$822934.7 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Immatics | 1.14 Bn | 1.14 Bn | - | 115.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 115.88 Mn |
| Dec 31, 2025 | 115.88 Mn |
| Sep 30, 2025 | -858,086.44 |
| Sep 30, 2025 | -858,086.44 |
| Jun 30, 2025 | -822,934.69 |
| Jun 30, 2025 | -822,934.69 |
| Mar 31, 2025 | -775,238.83 |
| Mar 31, 2025 | -775,238.83 |
| Dec 31, 2024 | 156.40 Mn |
| Dec 31, 2024 | 156.40 Mn |
| Sep 30, 2024 | -826,959.29 |
| Sep 30, 2024 | -826,959.29 |
| Jun 30, 2024 | -609,518.37 |
| Jun 30, 2024 | -609,518.37 |
| Mar 31, 2024 | 189.73 Mn |
| Mar 31, 2024 | 189.73 Mn |
| Dec 31, 2023 | -1.05 Mn |
| Dec 31, 2023 | -1.05 Mn |
| Sep 30, 2023 | 54.32 Mn |
| Sep 30, 2023 | 54.32 Mn |